Order Article Reprints

Erickson CA, Perez-Cano L, Pedapati EV, Painbeni E, Bonfils G, Schmitt LM, Sachs H, Nelson M, De Stefano L, Westerkamp G, et al. Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD. Biomedicines. 2024; 12(7):1430. https://doi.org/10.3390/biomedicines12071430

Erickson, Craig A., Laura Perez-Cano, Ernest V. Pedapati, Eric Painbeni, Gregory Bonfils, Lauren M. Schmitt, Hannah Sachs, Meredith Nelson, Lisa De Stefano, Grace Westerkamp, and et al. 2024. "Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD" Biomedicines 12, no. 7: 1430. https://doi.org/10.3390/biomedicines12071430

Erickson, C. A., Perez-Cano, L., Pedapati, E. V., Painbeni, E., Bonfils, G., Schmitt, L. M., Sachs, H., Nelson, M., De Stefano, L., Westerkamp, G., de Souza, A. L. S., Pohl, O., Laufer, O., Issachar, G., Blaettler, T., Hyvelin, J.-M., & Durham, L. A. (2024). Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD. Biomedicines, 12(7), 1430. https://doi.org/10.3390/biomedicines12071430